Key result
Selective P2Y12 inhibition provides clinical benefit and improves treatment for patients with CAD.
Why the study?
Selective P2Y12 inhibition has been clinically beneficial for decades, but new thienopyridine and nonthienopyridine antagonists are emerging to improve treatment of coronary disease.
This review highlights the historical success and future potential of P2Y12 antagonists in managing intravascular thrombosis in coronary disease.
Should not yet change CAD practice; leaves open optimal use of emerging P2Y12 antagonists pending new trials.
ADP plays a pivotal role in localized platelet activation and recruitment, and, with that, in the maintenance of thrombus integrity, making it a suitable target for the control of intravascular thrombosis. The limited distribution of one of its receptors, the P2Y12 receptor, primarily to platelets makes it an especially attractive pharmacologic target. For the last several decades the thienopyridine family of P2Y12 antagonists have provided the vast majority of clinical data confirming the clinical benefit of selective P2Y12 inhibition. Recently, new thienopyridine plus nonthienopyridine P2Y12 antagonists have become available or are being studied that will further improve our treatment of patients with coronary disease.
No takes yet. Share an insight, caveat, or question.
Barn et al. (2012) conducted a review in Coronary disease. P2Y12 antagonists was evaluated. Selective P2Y12 inhibition with thienopyridine and newer nonthienopyridine antagonists provides clinical benefit and will further improve the treatment of patients with coronary disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: